

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/013978 A1

(51) International Patent Classification⁷: **A61K 31/4045**,
C07D 209/08, 409/12, 513/04, A61P 3/04

(74) Agent: **DAVILA BAZ, A.**; Clarke, Modet & Co., C/Goya,
11, E-28001 Madrid (ES).

(21) International Application Number:
PCT/EP2004/008512

(22) International Filing Date: 29 July 2004 (29.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P 200301807 30 July 2003 (30.07.2003) ES

(71) Applicant (for all designated States except US): **LABO-
RATORIOS DEL DR. ESTEVE S.A.** [ES/ES]; Av. Mare
de Déu de Montserrat, 221, E-08041 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MERCE VI-
DAL, Ramon** [ES/ES]; C/Casanova 264 4° 1a, E-08021
Barcelona (ES). **CODONY SOLER, Xavier** [ES/ES];
C/Lepanto 71-77 2° 1a, E-08301 Mataro (ES). **DORDAL
ZUERAS, Alberto** [ES/ES]; C/Maladeta, 26 3° 3a,
E-08016 Barcelona (ES).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: INDOL-4 SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS




(Ia, Ib, Ic)

(57) Abstract: The present invention refers to new sulfonamide derivatives, of general formula (Ia, Ib, Ic), optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or their salt thereof s, preferably the corresponding, physiologically acceptable salt thereof s, or corresponding solvate thereof s; to the processes for their preparation, to their application as medicaments in human and/or veterinary therapeutics, and to the pharmaceutical compositions containing them.

INDOL-4 SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 RECEPTOR MODULATORS EAS

5 The present invention refers to new sulfonamide derivatives, of general formula (Ia, Ib, Ic),



(Ia, Ib, Ic)

10 optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or their salts, preferably the corresponding, physiologically acceptable salts, or corresponding solvates; to the processes for their preparation, to their
15 application as medicaments in human and/or veterinary therapeutics, and to the pharmaceutical compositions containing them.

 The new compounds of the present invention may be used in the pharmaceutical industry as intermediates and for preparing medicaments.

20

 The superfamily of serotonin receptors (5-HT) comprises 7 classes (5-HT₁-5-HT₇), which cover 14 human subclasses [D. Hoyer, et al., *Neuropharmacology*, 1997, 36, 419]. The 5-HT₆ receptor has been the last serotonin receptor identified by molecular cloning in rats [F.J. Monsma, et al., *Mol. Pharmacol.*, 1993, 43, 320; M. Ruat, et al., *Biochem. Biophys. Res. Commun.*, 1993, 193, 268] as well as in humans [R. Kohen, et al., *J. Neurochem.*, 1996, 66, 47]. The compounds with an affinity for the 5-HT₆

25

-2-

receptor are useful in treating different disorders of the Central Nervous System and of the Gastrointestinal system, as well as the irritable bowel syndrome. The compounds with an affinity for the 5-HT₆ receptor are useful for treating anxiety, depression and cognitive memory disorders [M. Yoshioka, et al., *Ann. NY Acad. Sci.*, 1998, 861, 244; A. Bourson, et al., *Br. J. Pharmacol.*, 1998, 125, 1562; D.C. Rogers, et al., *Br. J. Pharmacol. Suppl.*, 1999, 127, 22P; A. Bourson, et al., *J. Pharmacol. Exp. Ther.*, 1995, 274, 173; A.J. Sleight, et al., *Behav. Brain Res.*, 1996, 73, 245; T.A. Branchek, et al., *Annu. Rev. Pharmacol. Toxicol.*, 2000, 40, 319; C. Routledge, et al., *Br. J. Pharmacol.*, 2000, 130, 1606]. It has been shown that the typical and atypical antipsychotics for treating schizophrenia have a high affinity for the 5-HT₆ receptors [B.L. Roth, et al., *J. Pharmacol. Exp. Ther.*, 1994, 268, 1403; C.E. Glatt, et al., *Mol. Med.*, 1995, 1, 398; F.J. Mosma, et al., *Mol. Pharmacol.*, 1993, 43, 320; T. Shinkai, et al., *Am. J. Med. Genet.*, 1999, 88, 120]. The compounds with an affinity for the 5-HT₆ receptor are useful for treating infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder) [W.D. Hirst, et al., *Br. J. Pharmacol.*, 2000, 130, 1597; C. Gérard, et al., *Brain Research*, 1997, 746, 207; M.R. Pranzatelli, *Drugs of Today*, 1997, 33, 379].

Patent application WO 01/32646 discloses sulfonamides derived from bicycles, whereby each of the rings is 6-membered, aromatic or heteroaromatic rings with 5-HT₆ receptor antagonist activity.

Patent application EP 0 733 628 discloses sulfonamides derived from indole with 5-HT_{1F} receptor antagonist activity, useful for the treatment of migraines.

Furthermore, it has been shown that the 5-HT₆ receptor also plays a role in the ingestion of food [Neuropharmacology, 41, 2001, 210-219].

Eating disorders, particularly obesity, are a serious and increasingly frequent threat for the health of humans from all age groups, since they increase the risk of developing other serious and even mortal diseases, preferably diabetes and coronary artery diseases.

Therefore, an object of the present invention was to provide new compounds, particularly suitable as active substances in medicaments, preferably in medicaments for 5-HT₆ receptor regulation, for cognitive enhancement, for the prophylaxis and/or treatment of a disorder or disease
5 related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably
10 irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple Sclerosis, schizophrenia, psychosis or infantile
15 hyperkinesia (ADHD, attention deficit / hyperactivity disorder), and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in animals, preferably in mammals, more preferably in humans.

It has been found that the indol-4-yl sulfonamide compounds of general
20 formulas (Ia, Ib, Ic) described below show an affinity for the 5-HT₆ receptor.


These compounds are therefore suitable for preparing a medicament for preventing and/or treating disorders related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body
25 weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of
30 the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple

-4-

Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder), and other disorders mediated by the 5-HT₆ serotonin receptor in mammals, including man. These compounds are also suitable for the preparation of a medicament for cognitive enhancement.

5

Thus, one aspect of the present invention are compounds of general formula (Ia),



10

(Ia)

wherein

R¹ represents a -NR⁸R⁹ radical or a saturated or unsaturated, optionally at least
 15 mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

20

R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or heteroaryl radical,

25

R⁴ is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R⁸ and R⁹, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

5

with the proviso that R⁸ and R⁹ are not hydrogen at the same time, and if one of them, R⁸ or R⁹, is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C₁-C₄ aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms, or

10

R⁸ and R⁹ together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

15

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

20

and

25


n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

30

-6-

Another aspect of the present invention are compounds of general formula (Ib)



(Ib)

wherein

R^1 represents a $-NR^8R^9$ radical,

R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

R^4 is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^8 and R^9 , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_{1-4}

aliphatic radical,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

-7-


and

n is 0, 1, 2, 3 or 4;

- 5 optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

10

Yet another aspect of the present invention are compounds of general formula (Ic),



wherein

15

R¹ represents a -NR⁸R⁹ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one
 20 heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at
 25 least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

-8-

R⁴ represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

5 R⁸ and R⁹, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

10 R⁸ and R⁹ together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one
15 heteroatom as a ring member,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain
20 at least one heteroatom as a ring member in one or more of its rings,

and

n is 0, 1, 2, 3 or 4;

25

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt
30 thereof, or a corresponding solvate thereof.

If one or more of the moieties R^2 - R^9 represent a saturated or unsaturated aliphatic radical, that is, an alkyl, alkenyl or alkynyl radical which is substituted by one or more substituents, each one of these substituents may preferably be chosen, unless otherwise defined, from the group consisting of hydroxy,
5 fluorine, chlorine, bromine and trifluoromethyl.

If R^1 is a saturated or unsaturated, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which is substituted by one or more substituents and/or is condensed with a saturated or unsaturated, optionally at
10 least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, which is substituted by one or more substituents, each one of these substituents may preferably be chosen, unless otherwise defined, from the group consisting of hydroxy, fluorine, chlorine, bromine, linear or branched C_1 - C_6 alkyl, linear or branched C_1 - C_6 alkoxy, linear or branched C_1 -
15 C_6 perfluoroalkyl, linear or branched C_1 - C_6 perfluoroalkoxy and benzyl, preferably from the group consisting of linear or branched C_1 - C_6 alkyl and benzyl.

The heteroatoms of said cycloaliphatic radical and/or of said mono- or bicyclic
20 cycloaliphatic ring may, independently from one another, preferably be chosen from the group consisting of nitrogen, sulphur and oxygen, more preferably nitrogen is chosen as a heteroatom.

Said cycloaliphatic radical may contain 0, 1, 2 or 3 heteroatoms chosen
25 from the above mentioned group, preferably it contains 0, 1 or 2 heteroatoms chosen from the above mentioned group.

If R^8 and R^9 together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may
30 contain at least one further heteroatom as a ring member and/or which is condensed with a saturated or unsaturated mono- or bicyclic cycloaliphatic ring system, which may contain at least one heteroatom as a ring member and/or

-10-

which is substituted by one or more substituents, each one of these substituents may preferably be chosen, unless otherwise defined, from the group consisting of hydroxy, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ perfluoroalkyl, linear or branched C₁-C₆ perfluoroalkoxy and benzyl, preferably from the group consisting of linear or branched C₁-C₆ alkyl and benzyl.

If the heterocyclic ring contains one or more additional heteroatoms, and/or if one or both rings of the mono- or bicyclic ring system contain one or more heteroatoms, these heteroatoms may, independently from one another, preferably be chosen from the group consisting of nitrogen, sulphur and oxygen, more preferably nitrogen is chosen as a heteroatom.

Said heterocyclic ring may contain 0, 1, 2 or 3 additional heteroatoms chosen from the above mentioned group, preferably it contains 0 or 1 heteroatoms chosen from the above mentioned group.

If A is a mono- or polycyclic aromatic ring system which may be bonded via an alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member and/or which may be substituted by one or more substituents, each one of these substituents may preferably be chosen from the group consisting of hydroxy, halogen, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, -O-phenyl, linear or branched C₁-C₆ perfluoroalkyl, linear or branched C₁-C₆ perfluoroalkoxy, an optionally at least mono-substituted phenyl radical and 5- or 6-membered heteroaryl, more preferably from the group consisting of halogen, linear or branched C₁-C₆ alkyl, -O-phenyl, an optionally at least mono-substituted phenyl radical and 5- or 6-membered heteroaryl, even more preferably from the group consisting of fluorine, chlorine, -O-phenyl, linear or branched C₁-C₆ alkyl, an optionally at least mono-substituted phenyl radical and 5- or 6-membered heteroaryl.

If one or more of the rings of the mono- or polycyclic aromatic ring system contain one or more heteroatoms, these heteroatoms – like the heteroatoms of a previously mentioned 5- or 6-membered heteroaryl radical – may preferably be chosen from the group consisting of nitrogen, sulphur and oxygen.

If the previously mentioned phenyl radical is itself substituted by one or more substituents, each one of these substituents may preferably be chosen from the group consisting of fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, trifluoromethyl radical, cyano radical and a -NR¹²R¹³ radical, wherein R¹² and R¹³, identical or different, represent hydrogen or a linear or branched C₁-C₆ alkyl.

If the previously mentioned alkylene, alkenylene or alkynylene group is substituted by one or more substituents, each of these substituents may preferably be chosen from the group consisting of hydroxy, halogen, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ perfluoroalkyl, linear or branched C₁-C₆ perfluoroalkoxy or an optionally at least mono-substituted phenyl radical.

If said phenyl radical is itself substituted by one or more substituents, each one of these substituents may preferably be chosen from the group consisting of fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, trifluoromethyl radical, cyano radical and a -NR¹²R¹³ radical, wherein R¹² and R¹³, identical or different, represent hydrogen or a linear or branched C₁-C₆ alkyl.


If one or more of the substituents R², R³, R⁵, R⁶ and R⁷ represents an alkoxy radical, said radical may have 1 to 6, preferably 1 to 3 carbon atoms.

-12-

Those skilled in the art understand that the term "condensed" indicates that the condensed rings share more than one atom. The terms "annulated" or "fused" may also be used for this type of bonding.

- 5 Sulfonamide derivatives of general formula (Ia) are preferred, wherein R^1 represents a $-NR^8R^9$ radical or a saturated or unsaturated optionally at least mono-substituted 5- or 6-membered cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted
 10 mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- or 6-membered,

- more preferably R^1 represents a $-NR^8R^9$ radical or a radical chosen from the
 15 group consisting of



- wherein, if present, the dotted line represents an optional chemical bond, and R^{10} represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen or a C_1 - C_2 alkyl radical and R^2 - R^9 , A and n are
 20 defined as above.

-13-

Sulfonamide derivatives of general formula (Ia) are also preferred, wherein R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical,

more preferably R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

10

even more preferably R^2 , R^3 , R^5 , R^6 and R^7 each represent hydrogen or a C_1 - C_2 alkyl radical and R^1 , R^4 , R^8 , R^9 , A and n are defined as above.

Sulfonamide derivatives of general formula (Ia) are also preferred, wherein R^4 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical

more preferably R^4 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

even more preferably R^4 represents hydrogen or a C_1 - C_2 alkyl radical and R^1 , R^3 , R^5 - R^9 , A and n are defined as above.

25

Furthermore, sulfonamide derivatives of general formula (Ia) are also preferred, wherein R^8 and R^9 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkynyl radical,

30

with the proviso that R^8 and R^9 do not represent hydrogen at the same time, and if one of them, R^8 and R^9 , represents a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_1 - C_4 aliphatic radical, the other one represents a saturated or unsaturated, linear or branched,
5 optionally at least mono-substituted, aliphatic radical with at least five carbon atoms, or

R^8 and R^9 together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered heterocyclic ring which
10 may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- 6- or 7-membered and R^1 - R^7 , A and n are defined as above.


15

Particularly preferred are sulfonamide derivatives of general formula (Ia), wherein R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched C_1 - C_{10} alkyl radical,

with the proviso that R^8 and R^9 do not represent hydrogen at the same
20 time, and if one of them, R^8 and R^9 , represents a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_1 - C_4 aliphatic radical, the other one represents a saturated or unsaturated, linear or branched, optionally at least mono-substituted, aliphatic radical with at least five carbon atoms, or

25 R^8 and R^9 together with bridging nitrogen atom form a radical chosen from the group consisting of

-15-



wherein R^{11} , if present, represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen, or a C_1 - C_2 alkyl radical, and R^1 , R^9 , A and n are defined as above.

5

Furthermore, sulfonamide derivatives of general formula (Ia) are preferred, wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C_1 - C_6 alkylene group, an optionally at least mono-substituted C_2 - C_6 alkenylene group or an optionally at least mono-substituted C_2 - C_6 alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,


10

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

15

or a radical chosen from the group consisting of

-16-



wherein X, Y, Z, independently from one another, each represent a radical
 5 selected from the group consisting of hydrogen, fluorine, chlorine, bromine,
 linear or branched C_1 - C_6 alkyl, linear or branched C_1 - C_6 alkoxy, linear or
 branched C_1 - C_6 alkylthio, a trifluoromethyl radical, a cyano radical and a -
 $NR^{12}R^{13}$ radical,

10 wherein R^{12} and R^{13} , identical or different, each represent hydrogen or linear or
 branched C_1 - C_6 alkyl,

W represents a single chemical bond between the two rings, a CH_2 , O, S group
 15 or a NR^{14} radical,

wherein R^{14} is hydrogen or a linear or branched C_1 - C_6 alkyl,


m is 0, 1, 2, 3 or 4 and

-17-

m1 is 1 or 2, preferably 2, and R^1 - R^9 and n are defined as above.

Furthermore, sulfonamide derivatives of general formula (Ia) are preferred, wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C_1 - C_6 alkylene group, an optionally at least mono-substituted C_2 - C_6 alkenylene group or an optionally at least mono-substituted C_2 - C_6 alkynylene group, and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

more preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom, or a radical chosen from the group consisting of



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C_1 - C_6 alkyl, linear or branched C_1 - C_6 alkoxy, linear or branched C_1 - C_6 alkylthio, a trifluoromethyl radical, a cyano radical and a - $NR^{12}R^{13}$ radical,

wherein R^{12} and R^{13} , identical or different, each represent hydrogen or linear or branched C_1 - C_6 alkyl,

-18-

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

5

and


m is 0, 1, 2, 3 or 4.

10 and R¹-R⁹ and n are defined as above.


Furthermore, sulfonamide derivatives of general formula (Ia) are preferred, wherein A represents a heteroaryl radical selected from the group consisting of benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl which may be substituted by 1, 2 or 3 substituents selected from the group consisting of chlorine, methyl, phenyl and -O-phenyl and/or which may be bonded via a C₁₋₂ alkylene group,

15

or a radical chosen from the group consisting of



-19-



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine,
 5 linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or
 10 branched C₁-C₆ alkyl,

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

15 wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

m is 0, 1, 2, 3 or 4 and

m₁ is 1 or 2, preferably 2, and R¹-R⁹ and n are defined as above.

20

Furthermore sulfonamide derivatives of general formula (Ia) are preferred, wherein n is 0, 1, 2, 3 or 4; preferably n is 1 or 2; more preferably n is 2 and R¹ to R⁹ and A are defined as above.

25

Furthermore, sulfonamide derivatives of general formula (Ib) are also preferred, wherein R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen, a linear or branched C₁-C₆ alkyl radical, a linear or branched, optionally at least mono-substituted C₁-C₆ alkyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkenyl radical, or a linear or

-20-

branched, optionally at least mono-substituted C₂-C₆ alkynyl radical,

more preferably R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C₁-C₆ alkyl radical,

more preferably R², R³, R⁵, R⁶ and R⁷ each represent hydrogen or a C₁₋₂ alkyl radical and R¹, R⁴, R⁸, R⁹, A and n are defined as above.

Sulfonamide derivatives of general formula (Ib) are also preferred, wherein R⁴ represents hydrogen, a linear or branched, optionally at least mono-substituted C₁-C₆ alkyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkenyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkynyl radical,

more preferably that R⁴ represents hydrogen or a linear or branched, optionally at least mono-substituted C₁-C₆ alkyl radical,

even more preferably R⁴ represents hydrogen or a C₁-C₂ alkyl radical and R¹-R³, R⁵-R⁹, A and n are defined as above.

Furthermore, sulfonamide derivatives of general formula (Ib) are also preferred, wherein R⁸ and R⁹, identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C₁-C₄ alkyl radical, and R¹-R⁷, A and n are defined as above.


Particularly preferred are sulfonamide derivatives of general formula (Ib) wherein R⁸ and R⁹, identical or different, each represent hydrogen or a C₁-C₂ alkyl radical, with the proviso that R⁸ and R⁹ are not hydrogen at the same time, and R¹-R⁷, A and n are defined as above.

-21-

Furthermore, sulfonamide derivatives of general formula (Ib) are preferred, wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C₁–C₆ alkylene group, an optionally at least mono-substituted C₂–C₆ alkenylene group or an optionally at least mono-substituted C₂–C₆ alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

or a radical chosen from the group consisting of



15

wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁–C₆ alkyl, linear or branched C₁–C₆ alkoxy, linear or branched C₁–C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -

20

-22-

NR¹²R¹³ radical,

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

5

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

10

m is 0, 1, 2, 3 or 4 and

m₁ is 1 or 2, preferably 2, and R¹-R⁹ and n are defined as above.

15


Furthermore, sulfonamide derivatives of general formula (Ib) are preferred, wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C₁-C₆ alkylene group, an optionally at least mono-substituted C₂-C₆ alkenylene group or an optionally at least mono-substituted C₂-C₆ alkynylene group, and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

20

more preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom, or a radical chosen from the group consisting of

25

-23-



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C_1 - C_6 alkyl, linear or branched C_1 - C_6 alkoxy, linear or branched C_1 - C_6 alkylthio, a trifluoromethyl radical, a cyano radical and a -
 5 $NR^{12}R^{13}$ radical,

wherein R^{12} and R^{13} , identical or different, each represent hydrogen or linear or branched C_1 - C_6 alkyl,

10

W represents a single chemical bond between the two rings, a CH_2 , O, S group or a NR^{14} radical,

wherein R^{14} is hydrogen or a linear or branched C_1 - C_6 alkyl,

15

and


m is 0, 1, 2, 3 or 4.

20 and R^1 - R^9 and n are defined as above.

-24-

Furthermore, sulfonamide derivatives of general formula (Ib) are preferred,
 wherein A represents a heteroaryl radical selected from the group consisting of
 benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl which may be substituted by 1, 2
 or 3 substituents selected from the group consisting of chlorine, methyl, phenyl
 5 and -O-phenyl and/or which may be bonded via a C₁₋₂ alkylene group,

or a radical chosen from the group consisting of



10

wherein X, Y, Z, independently from one another, each represent a radical
 selected from the group consisting of hydrogen, fluorine, chlorine, bromine,
 linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or
 branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -
 15 NR¹²R¹³ radical,

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or
 branched C₁-C₆ alkyl,

20 W represents a single chemical bond between the two rings, a CH₂, O, S group

-25-

or a NR^{14} radical,

wherein R^{14} is hydrogen or a linear or branched $\text{C}_1\text{-C}_6$ alkyl,

5 m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2, preferably 2, and $\text{R}^1\text{-R}^9$ and n are defined as above.

Furthermore sulfonamide derivatives of general formula (Ib) are preferred,
wherein n is 0, 1, 2, 3 or 4; preferably n is 1 or 2; more preferably n is 2 and R^1
10 to R^9 and A are defined as above.

The most preferred compounds of general formula (Ib) are selected from
the group consisting of

- 15 [1] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [2] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphthalene-2-sulfonamide,
- 20 [3] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphthalene-1-sulfonamide,
- [4] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenylbenzenesulfonamide,
- 25 [5] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-2-(naphthalene-1-yl)-ethanesulfonamide,
- [6] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenoxybenzenesulfonamide,
- 30 [7] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-3,5-dichlorobenzenesulfonamide and


[8] 6-chloro-N-[1-(2-dimethylaminoethyl)-1H-indol-4-yl]-imidazo[2,1-b]thiazole-5-sulfonamide

5 and their corresponding salts and solvates.

Sulfonamide derivatives of general formula (Ic) are preferred, wherein R^1 represents a $-NR^8R^9$ radical or a saturated or unsaturated optionally at least mono-substituted 5- or 6-membered cycloaliphatic radical, which may optionally
 10 contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- or 6-membered,

15

more preferably R^1 represents a $-NR^8R^9$ radical or a radical chosen from the group consisting of



wherein, if present, the dotted line represents an optional chemical bond, and
 20 R^{10} represents hydrogen, a linear or branched C_1-C_6 alkyl radical or a benzyl radical, preferably hydrogen or a C_1-C_2 alkyl radical and R^2-R^9 , A and n are defined as above.

-27-

Sulfonamide derivatives of general formula (Ic) are also preferred, wherein R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical,

more preferably R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

10

even more preferably R^2 , R^3 , R^5 , R^6 and R^7 each represent hydrogen or a C_{1-2} alkyl radical and R^1 , R^4 , R^8 , R^9 , A and n are defined as above.

Sulfonamide derivatives of general formula (Ic) are also preferred, wherein R^4 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical

more preferably R^4 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

even more preferably R^4 represents hydrogen or a C_1 - C_2 alkyl radical and R^1 , R^3 , R^5 - R^9 , A and n are defined as above.

25

Furthermore, sulfonamide derivatives of general formula (Ic) are also preferred, wherein R^8 and R^9 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkynyl radical, or R^8 and R^9 together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered heterocyclic ring which

30


-28-

may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system
 5 are 5- 6- or 7-membered and R^1 - R^7 , A and n are defined as above.

Particularly preferred are sulfonamide derivatives of general formula (Ic), wherein R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched C_1 - C_{10} alkyl radical, or

10

R^8 and R^9 together with bridging nitrogen atom form a radical chosen from the group consisting of




wherein R^{11} , if present, represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen, or a C_1 - C_2 alkyl radical, and R^1 - R^9 , A and n are defined as above.
 15

Furthermore, sulfonamide derivatives of general formula (Ic) are preferred, wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered,
 20 which may be bonded via an optionally at least mono-substituted C_1 - C_6 alkylene group, an optionally at least mono-substituted C_2 - C_6 alkenylene group or an optionally at least mono-substituted C_2 - C_6 alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

5

or a radical chosen from the group consisting of



- 10 wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

15

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

- 20 W represents a single chemical bond between the two rings, a CH₂, O, S group

-30-

or a NR^{14} radical,


wherein R^{14} is hydrogen or a linear or branched $\text{C}_1\text{-C}_6$ alkyl,

5 m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2, preferably 2, and $\text{R}^1\text{-R}^9$ and n are defined as above.

Furthermore, sulfonamide derivatives of general formula (Ic) are
 10 preferred, wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted $\text{C}_1\text{-C}_6$ alkylene group, an optionally at least mono-substituted $\text{C}_2\text{-C}_6$ alkenylene group or an optionally at least mono-substituted $\text{C}_2\text{-C}_6$ alkynylene group, and/or
 15 wherein the ring(s) may contain at least one heteroatom as a ring member,

more preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,
 20 or a radical chosen from the group consisting of



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched $\text{C}_1\text{-C}_6$ alkyl, linear or branched $\text{C}_1\text{-C}_6$ alkoxy, linear or

-31-

branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or
5 branched C₁-C₆ alkyl,

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

10 wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

and

m is 0, 1, 2, 3 or 4.


15

and R¹-R⁹ and n are defined as above.

Furthermore, sulfonamide derivatives of general formula (Ic) are preferred,
wherein A represents a heteroaryl radical selected from the group consisting of
20 benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl which may be substituted by 1, 2
or 3 substituents selected from the group consisting of chlorine, methyl, phenyl
and -O-phenyl and/or which may be bonded via a C₁₋₂ alkylene group,

or a radical chosen from the group consisting of

-32-



wherein X, Y, Z, independently from one another, each represent a radical
 5 selected from the group consisting of hydrogen, fluorine, chlorine, bromine,
 linear or branched C_1 - C_6 alkyl, linear or branched C_1 - C_6 alkoxy, linear or
 branched C_1 - C_6 alkylthio, a trifluoromethyl radical, a cyano radical and a -
 $NR^{12}R^{13}$ radical,

10 wherein R^{12} and R^{13} , identical or different, each represent hydrogen or linear or
 branched C_1 - C_6 alkyl,

W represents a single chemical bond between the two rings, a CH_2 , O, S group
 or a NR^{14} radical,

15

wherein R^{14} is hydrogen or a linear or branched C_1 - C_6 alkyl,


m is 0, 1, 2, 3 or 4 and

20 m_1 is 1 or 2, preferably 2, and R^1 - R^9 and n are defined as above.

-33-

Furthermore sulfonamide derivatives of general formula (Ic) are preferred, wherein n is 0, 1, 2, 3 or 4; preferably n is 1 or 2; more preferably n is 2 and R¹ to R⁹ and A are defined as above.

- 5 Yet another aspect of the present invention are compounds of general formula (Ic),



wherein

- 10 R¹ represents a -NR⁸R⁹ radical,

R², R³, R⁵, R⁶ and R⁷ each represent hydrogen,

R⁴ represents hydrogen,

15

R⁸ and R⁹, identical or different, each represent methyl, ethyl, n-propyl, iso-propyl, more preferably methyl,

and

20

A represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl which may be substituted by 1, 2 or 3 substituents selected from the group consisting of chlorine, methyl, phenyl and -O-phenyl and/or which may be bonded via a C₁₋₂ alkylene group,

25

and

-34-

n is 2;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

The most preferred compounds of general formula (Ic) are selected from the group consisting of


- [1] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [2] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphthalene-2-sulfonamide,
- [3] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphthalene-1-sulfonamide,
- [4] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenylbenzenesulfonamide,
- [5] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-2-(naphthalene-1-yl)-ethanesulfonamide,
- [6] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenoxybenzenesulfonamide,
- [7] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-3,5-dichlorobenzenesulfonamide and
- [8] 6-chloro-N-[1-(2-dimethylaminoethyl)-1H-indol-4-yl]-imidazo[2,1-b]thiazole-5-sulfonamide

and their corresponding salts and solvates.

The present invention likewise refers to the salts, preferably the
5 physiologically acceptable salts of the compounds of general formula (Ia) and/or
(Ib) and/or of general formula (Ic), preferably the addition salts of mineral acids,
more preferably of hydrochloric acid, hydrobromic acid, phosphoric acid,
sulphuric acid, nitric acid, and the salts of organic acids, more preferably of citric
acid, maleic acid, fumaric acid, tartaric acid or their derivatives, *p*-
10 toluenesulphonic acid, methanesulphonic acid, camphorsulphonic acid, etc.

Below, the expression sulfonamide derivatives refers to the general
formula (I), to one or more compounds of general formula (Ia) and/or to one or
more compounds of general formula (Ib) and/or to one or more compounds of
15 general formula (Ic), respectively, and optionally in form of one of their
stereoisomers, preferably enantiomers or diastereomers, their racemate, or in
form of a mixture of at least two of their stereoisomers, preferably enantiomers
or diastereomers, in any mixing ratio, or a salt thereof, preferably a
corresponding physiologically acceptable salt thereof, or a corresponding
20 solvate thereof.

Another aspect of the present invention consists of a process for
obtaining the new derivatives of general formula (I), wherein R^1 - R^9 , *n* and A
have the previously indicated meaning, according to which at least one
25 compound of general formula (II),




(II)

wherein A has the previously mentioned meaning, and X is an acceptable
leaving group, preferably an halogen atom, more preferably chlorine; is reacted

-36-

with at least one substituted 4-aminoindole of general formula (III)



(III)

wherein R^1 - R^7 and n have the previously indicated meaning, or one of their
5 suitable protected derivatives, and, if necessary, the protective groups are removed in order to obtain the corresponding sulfonamide derivative of formula (I), which may be purified and/or isolated via conventional methods known in the prior art.

10 The reaction between the compounds of general formula (II) and (III) is usually carried out in the presence of an organic reaction medium, preferably in the presence of dialkyl ether, more preferably diethyl ether or a cyclic ether, more preferably tetrahydrofuran or dioxane, an halogenated organic hydrocarbon, more preferably methylene chloride or chloroform, an alcohol,
15 more preferably methanol or ethanol, a dipolar aprotic solvent, more preferably acetonitrile, pyridine or dimethylformamide, or any other suitable reaction medium. Naturally, mixtures of at least two of the classes of the mentioned compounds or at least two compounds of one class may also be used.

20 The reaction is preferably carried out in the presence of a suitable base, for example, an inorganic base, more preferably alkaline metal hydroxides and alkaline metal carbonates, or in the presence of an organic base, more preferably triethylamine, N-ethyl-diisopropylamine or pyridine.

25 The most suitable reaction temperatures range from 0 °C to room temperature, that is, approximately 25 °C, and the reaction time is preferably from 5 minutes to 24 hours.

The resulting sulfonamide derivative of general formula (I) may be purified and/or isolated according to conventional methods known in the prior art.

5 Preferably, the sulfonamide derivatives of general formula (I) may be isolated by evaporating the reaction medium, adding water and, if necessary, adjusting the pH so that a solid which may be isolated by filtration is obtained; or the sulfonamide derivatives may be extracted with a water immiscible solvent, preferably chloroform, and be purified by chromatography or
10 recrystallization of a suitable solvent.

 The compounds of general formula (II) are commercially available, or they may be prepared according to standard methods known in the prior art, for example by methods similar to those described in the literature [E.E.Gilbert,
15 Synthesis, 1969, 1, 3]. The compounds of general formula (III) may also be prepared according to standard methods known in the prior art, for example by methods similar to those described in: [Abou-Gharbia, Magid; Patel, Usha; Tokolics, Joseph; Freed, Meier. European Journal of Medicinal Chemistry (1988), 23(4), 373-7]. The respective literature descriptions are incorporated by
20 reference and form part of the disclosure.

 Another aspect of the present invention consists in a process for preparing the new sulfonamide derivatives of general formula (I), wherein R^1 - R^3 , R^5 - R^9 , n and A have the previously indicated meaning and R^4 is an alkyl radical,
25 preferably a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, by alkylation of a sulfonamide derivative of general formula (I), wherein R^1 - R^3 , R^5 - R^7 , n and A have the previously indicated meaning, and R^4 is an hydrogen atom, with an alkyl halogenide or a dialkyl sulfate.

30 The alkylation reaction is carried out preferably in the presence of a suitable base, more preferably in the presence of alkaline metal hydroxides and alkaline metal carbonates, metal hydrides, metal alkoxides, even more

preferably sodium methoxide or potassium tert-butoxide, organometallic compounds, even more preferably butyllithium or tert-butyllithium, in the presence of an organic reaction medium, more preferably dialkyl ether, even more preferably diethyl ether, or a cyclic ether, even more preferably
5 tetrahydrofuran or dioxane, an hydrocarbon, even more preferably toluene, an alcohol, even more preferably methanol or ethanol, a dipolar aprotic solvent, even more preferably acetonitrile, pyridine or dimethylformamide, or any other suitable reaction medium. Naturally, mixtures of at least two of the classes of the mentioned compounds or at least two compounds of one class may also be
10 used.

The most suitable reaction temperatures range from 0 °C to the boiling temperature of the reaction medium, and the reaction times are preferably from 1 to 24 hours.

15 Preferably, the resulting sulfonamide derivative of general formula (I) may be isolated by filtration, concentrating the filtrate under reduced pressure, adding water and, if necessary, adjusting the pH so that a solid which may be isolated by filtration is obtained; or the sulfonamide derivatives may be
20 extracted with a water immiscible solvent, preferably chloroform, and be purified by chromatography or recrystallization of a suitable solvent.

The salts, preferably pharmaceutically acceptable salts of the compounds of general formula (I), may be prepared by means of conventional
25 methods known in the prior art, preferably by reaction with a mineral acid, more preferably by reaction with hydrochloric acid, hydrobromic acid, phosphoric acid acid, sulphuric acid or nitric acid, or by reaction with organic acids, more preferably by reaction with citric acid, maleic acid, fumaric acid acid, tartaric acid, or their derivatives, *p*-toluenesulphonic acid, methanesulphonic acid,
30 camphorsulphonic acid, etc., in a suitable solvent, preferably methanol, ethanol, diethyl ether, ethyl acetate, acetonitrile or acetone, and obtaining the resulting salts by using the usual techniques for the precipitation or crystallization of the

corresponding salts.

5 The preferred physiologically acceptable salts of the sulfonamide derivatives of general formula (I) are the addition salts of mineral acids, more preferably of hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid or nitric acid, and the addition salts of organic acids, more preferably citric acid, maleic acid, fumaric acid, tartaric acid, or their derivatives, *p*-toluenesulphonic acid, methanesulphonic acid, camphorsulphonic acid, etc.

10 The solvates, preferably the physiologically acceptable solvates, more preferably hydrates, of the sulfonamide derivatives of general formula (I) or of the corresponding physiologically acceptable salts, may be prepared by methods known in the prior art.

15 During some of the synthetic sequences described or in the preparation of the suitable reagents used, it may be necessary and/or desirable to protect sensitive or reactive groups in some of the molecules used. This may be carried out via the use of conventional protective groups preferably those described in the literature [Protective groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; T.W. Greene & P.G.M. Wuts, Protective Groups in
20 Organic Chemistry, John Wiley & Sons, 1991]. The protective groups may be removed in the suitable subsequent stage by methods known in the prior art. The respective literature descriptions are incorporated by reference and form part of the disclosure.

25

If the sulfonamide derivatives of general formula (I) are obtained in form of a mixture of stereoisomers, preferably enantiomers or diastereomers, said mixtures may be separated via standard processes known in the prior art, for example chromatographic methods or crystallization with chiral agents.

30

Another aspect of the present invention is a medicament comprising at least one indol-4-yl sulfonamide derivative of general formula (I), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate, or in form of a mixture of at least two of its stereoisomers, preferably
5 enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable adjuvants.

This medicament is suitable for 5-HT₆ receptor regulation, for the prophylaxis
10 and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or
15 treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's
20 disease, Huntington's disease and/or Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder), and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in animals, preferably in mammals, more preferably in humans.

25 Another aspect of the present invention is a medicament comprising at least one indol-4-yl sulfonamide derivative of general formula (Ia), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate, or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding
30 physiologically acceptable salt thereof or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable adjuvants.

-41-

This medicament is suitable for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder) in humans and/or in animals, preferably in mammals, more preferably in humans, more suitable preferably for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome.

Another aspect of the present invention is a medicament comprising at least one indol-4-yl sulfonamide derivative of general formula (Ib), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate, or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable adjuvants.

This medicament is suitable for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder), and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in animals, preferably in mammals, more preferably in humans,

more suitable for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder), and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in animals, preferably in mammals, more preferably in humans.

25

Another aspect of the present invention is a medicament comprising at least one indol-4-yl sulfonamide derivative of general formula (Ic), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate, or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable adjuvants.

30

This medicament is suitable for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder), and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in animals, preferably in mammals, more preferably in humans.

The medicament obtained according to the present invention is particularly suitable for the administration to mammals, including humans. The medicament may preferably be administered to all age groups, namely, children, adolescents and adults.

Another aspect of the present invention is the use of at least one sulfonamide derivative of general formula (I), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate, or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof, for the manufacture of a medicament for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia,

cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder) and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in animals, preferably in mammals, more preferably in humans.

Another aspect of the present invention is the use of at least one sulfonamide derivative of the previous general formula (Ia), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate, or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof, for the manufacture of a medicament for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder) and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in

animals, preferably in mammals, more preferably in humans,

more preferably for the manufacture of a medicament for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance,
5 increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome in humans and/or in animals, preferably in mammals,
10 more preferably in humans.

Another aspect of the present invention is the use of at least one sulfonamide derivative of the previous general formula (Ib), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its
15 racemate, or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof, for the manufacture of a medicament for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake,
20 preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel
25 syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple Sclerosis, schizophrenia, psychosis
30 or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder) and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in animals, preferably in mammals, more preferably in humans,

more preferably the manufacture of a medicament for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder) in humans and/or in animals, preferably in mammals, more preferably in humans.

Another aspect of the present invention is the use of at least one sulfonamide derivative of general formula (Ic), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate, or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof, for the manufacture of a medicament for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and Multiple Sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder) and other disorders mediated by the 5-HT₆ serotonin receptor in humans and/or in animals, preferably in mammals, more preferably in humans.

The preparation of the corresponding pharmaceutical compositions as well as of the formulated medicaments may be carried out via conventional methods known in the prior art, for example, based on the indices of "Pharmaceutics: The Science of Dosage Forms", Second Edition, Aulton, M.E. (ED. Churchill Livingstone, Edinburgh (2002)); "Encyclopedia of Pharmaceutical Technology", Second Edition, Swarbrick, J. and Boylan, J.C. (Eds.), Marcel Dekker, Inc. New York (2002); "Modern Pharmaceutics", Fourth Edition, Banker G.S. and Rhodes C.T. (Eds.) Marcel Dekker, Inc. New York (2002), and "The Theory and Practice of Industrial Pharmacy", Lachman L., Lieberman H. and Kanig J. (Eds.), Lea & Febiger, Philadelphia (1986). The respective literature descriptions are incorporated as a reference and are part of this disclosure.

The pharmaceutical compositions, as well as the formulated medicaments prepared according to the present invention, may, in addition to at least one sulfonamide derivative of general formula (I), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate, or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof, comprise other conventional auxiliary substances known in the prior art, preferably excipients, fillers, solvents, diluents, dyes, coating agents, matrix forming agents and/or binders. As the skilled persons in the art also knows, the choice of the auxiliary substances and the amounts thereof depend on the intended administration route, for example, rectal, intravenous, intraperitoneal, intramuscular, intranasal, oral, buccal or topical.

Medicaments suitable for oral administration are, for example, tablets, coated tablets, capsules or multiparticulates, preferably granules or pellets, optionally subjected to compression in tablets, filled in capsules or suspended in solutions, suspensions or suitable liquids.

Medicaments suitable for parenteral, topical or inhalatory administration may preferably be chosen from the group consisting of solutions, suspensions, quickly reconstitutable dry preparations and also sprays.

5 Medicaments suitable for oral or percutaneous use may release the sulfonamide compounds of general formula (I) in a sustained manner, the preparation of these sustained release medicaments generally being known in the prior art.

10 Suitable sustained release forms, as well as the materials and methods for the preparation thereof, are known in the art, for example from the indices of "Modified-Release Drug Delivery Technology", Rathbone, J.JI, Hadgraft, J. and Roberts, M.S. (Eds.), Marcel Dekker, Inc., New York (2002); "Handbook of Pharmaceutical Controlled Release Technology", Wise, D.L. (Ed.), Marcel
15 Dekker, Inc. New York (2000); "Controlled Drug Delivery", Vol. I, Basic Concepts, Bruck, S.D. (Ed.), CRD Press, Inc., Boca Raton (1983), and by Takada, K. and Yoshikawa, H., "Oral Drug Delivery", Encyclopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 728-742; Fix, J., "Oral drug delivery, small intestine and colon",
20 Encyclopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 698-728. The respective literature references are incorporated by reference and form part of the disclosure.

The medicament of the present invention may also have at least one
25 enteric coating, which dissolves according to the pH. As a result of this coating, the medicament may pass through the stomach without dissolving, and the compounds of general formula I are only released in the intestinal tract. The enteric coating preferably dissolves at a pH of between 5 and 7.5. The materials and methods suitable for preparing enteric coatings are also known in the prior
30 art.

Typically, the pharmaceutical compositions and the medicaments comprise from 1 to 60% by weight of one or more sulfonamide derivatives of general formula (I), and from 40 to 99% by weight of one or more excipients.

- 5 The drug substance amount to be administered to the patient varies according to the patient's weight, the administration route, the indication and the severity of the disorder. Usually from 1 mg to 2 g of at least one sulfonamide derivative of general formula (I) are administered per patient per day. The total daily dose may be administered to the patient in one or more doses.

Pharmaceutical Methods:**BINDING TO THE 5HT₆ SEROTONIN RECEPTOR**

5 HEK-293 cell membranes expressing the recombinant human 5HT₆ receptor were supplied by Receptor Biology. The receptor concentration in said membranes is 2.18 pmol/mg of protein and the protein concentration is 9.17 mg/ml. The experimental protocol follows the method of B.L. Roth et al. [B.L. Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma, Y. Shen, H.Y. Meltzer, D.R. Sibley: Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and Hydroxytryptamine-7 Receptors. *The Journal of Pharmacology and Experimental Therapeutics*, 1994, 268, 1403], with slight
10 modifications. The commercial membrane is diluted (1:40 dilution) with the binding buffer: 50 mM Tris-HCl, 10 mM MgCl₂, 0.5 mM EDTA (pH 7.4). The radioligand used is [³H]-LSD at a concentration of 2.7 nM, the final volume being 200 µl. Incubation begins by adding 100 µl of the membrane suspension (≈ 22.9 µg of membrane protein), and is prolonged for 60 minutes at a temperature of 37°C. Incubation ends by quick filtration in a Harvester Brandel Cell through fiberglass filters of the Schleicher & Schuell GF 3362 trademark,
20 pretreated with a 0.5% polyethyleneimine solution. The filters are washed three times with three milliliters of 50 mM Tris HCl buffer, pH 7.4. The filters are transferred to vials and 5 ml of Ecoscint H. liquid scintillation cocktail are added to each vial. The vials are left to equilibrate for several hours prior to their counting in a 1414 Wallac Winspectral scintillation counter. The non-specific
25 binding is determined in the presence of 100 µM of serotonin. The assays are carried out in triplicate. The inhibition constants (K_i, nM) are calculated by non-linear regression analysis using the EBDA/LIGAND program [Munson and Rodbard, *Analytical Biochemistry*, 1980, 107, 220].

30 The respective literature descriptions are incorporated by reference and form part of the disclosure.

MEASUREMENTS OF FOOD INGESTION (BEHAVIOURAL MODEL)

Male W rats (200-270 g) from Harlan, S.A. are used. The animals are acclimatized to the housings during at least 5 days prior to being subjected to any treatment. During this period, the animals are housed (in groups of five) in translucent cages and have free access to water and food. The animals are housed in individual cages at least 24 hours prior to starting the treatment.

The acute effect of the sulfonamide derivatives of formula (I) used inventively on food ingestion in rats in fasting conditions is then determined as follows:

The rats are kept in fasting conditions for 23 hours in their individual cages. After this period, the rats are orally or intraperitoneally treated with a dose of a composition containing a sulfonamide derivative of general formula (I) or a corresponding composition (vehicle) without said sulfonamide derivative. Immediately after this, the rat is left with pre-weighed food and the accumulated food intake is measured after 1, 2, 4 and 6 hours.

This food ingestion measuring method is also described in publications of Kask et al., *European Journal of Pharmacology* 414 (2001), 215-224, and Turnbull et al., *Diabetes*, Vol. 51, August, 2002. The respective bibliographic descriptions are incorporated as a reference and they form part of the disclosure.

The preparation of new compounds according to the invention is indicated in the following examples. The affinity for the 5HT₆ serotonin receptor, as well as the galenic formulas applicable to the compounds of the invention, is also described. The examples indicated below, given as an illustrative example, should in no way limit the scope of the invention.

Examples:

Example 1.- Preparation of N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-5-chloro-3-methyl-benzo[b]thiophene-2-sulfonamide

185.5 mg (0.66 mMol) of 5-chloro-3-methyl-benzo[b] thiophene-2-sulfonyl chloride were added to a solution of 122 mg (0.6 mMol) of 4-amino-3-(2-dimethylaminoethyl)-1H-indole in 2 ml of dimethylformamide and 116 mg of N-ethyl-diisopropylamine. The reaction mixture was stirred at the room temperature for 20 hours. Then it was evaporated to dryness, slightly alkalized with sodium bicarbonate solution and extracted with chloroform. The organic phase was repeatedly washed with water and saturated solution of sodium bicarbonate, it was separated and dried with anhydrous sodium sulfate. The organic solution was evaporated to dryness and the resulting solid was purified by chromatography, obtaining 111 mg (42%) of N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-5-chloro-3-methyl-benzo[b]thiophene-2-sulfonamide as a creamy solid.

Example 2.- Preparation of N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphthalene-2-sulfonamide

121 mg (51%) of the mentioned compound were obtained from 122 mg (0.6 mMol) of 4-amino-1-(2-dimethylaminoethyl)-1H-indole and 149.5 mg (0.66 mMol) of naphthalene-2-sulfonyl chloride, via the process described in the Example 1, as a creamy solid.

-53-

Example 3.- Preparation of N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphthalene-1-sulfonamide

130 mg (55%) of the mentioned compound are obtained from 122 mg (0.6 mMol) of 4-amino-1-(2-dimethylaminoethyl)-1H-indole and 149.5 mg (0.66 mMol) of naphthalene-1-sulfonyl chloride, via the process described in the Example 1, as a creamy solid.

Example 4.- Preparation of N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenylbenzenesulfonamide

107 mg (42%) of the mentioned compound were obtained from 122 mg (0.6 mMol) of 4-amino-1-(2-dimethylaminoethyl)-1H-indole and 169 mg (0.66 mMol) of 4-phenylbenzenesulfonyl chloride, via the process described in the Example 1, as a creamy solid.

Example 5.- Preparation of N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-2-(naphthalene-1-yl)-ethanesulfonamide

52 mg (21%) of the mentioned compound were obtained from 122 mg (0.6 mMol) of 4-amino-1-(2-dimethylaminoethyl)-1H-indole and 168 mg (0.66 mMol) of 2-(naphthalene-1-yl)-ethanesulfonyl chloride, via the process described in the Example 1, as a yellowish solid.

Example 6.- Preparation of N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenoxybenzenesulfonamide

220 mg (84%) of the mentioned compound were obtained from 122 mg (0.6 mMol) of 4-amino-1-(2-dimethylaminoethyl)-1H-indole and 177 mg (0.66 mMol) of 4-phenoxybenzenesulfonyl chloride, via the process described in the Example 1, as a oil.

Example 7.- Preparation of N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-3,5-dichlorobenzenesulfonamide


93 mg (38%) of the mentioned compound are obtained from 122 mg (0.6 mMol)
5 of 4-amino-1-(2-dimethylaminoethyl)-1H-indole and 162 mg (0.66 mMol) of 3,5-dichlorobenzenesulfonyl chloride, via the process described in Example 1, as a creamy solid.

Example 8.- Preparation of 6-chloro-N-[1-(2-dimethylaminoethyl)-1H-indol-4-yl]-
10 imidazo[2,1-b]thiazole-5-sulfonamide


100 mg (39%) of the mentioned compound are obtained from 122 mg (0.6
mMol) of 4-amino-1-(2-dimethylaminoethyl)-1H-indole and 170 mg (0.66 mMol)
of 6-chloro-imidazo[2,1-b]-thiazole-5-sulfonyl chloride via the process described
15 in Example 1 as a creamy solid.


The yields are indicative and no added effort was made to improve them.


The melting point and spectroscopic data for identifying some of the
20 compounds of the present invention are indicated in the following table.






Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	n	A	m.p. °C	IR cm ⁻¹	¹ H-NMR (300 MHz), δ (solvent)
1	(CH ₃) ₂ N-	H	H	H	H	H	H	2		78-80	3430, 2951, 1492, 1328, 1156, 1115, 1079, 859, 750, 649, 569.	2,10(s, 6H); 2,28(s, 3H); 2,50(m, 2H); 4,14(t, 2H, J=6,3 Hz); 6,43(d, 1H, J=2,0 Hz); 6,92(d, 1H, J=7,5 Hz); 7,00(t, 1H, J=7,7 Hz); 7,17(d, 1H, J=2,2 Hz); 7,25(d, 1H, J=7,5 Hz); 7,49(d, 1H, J=8,4 Hz); 7,85(s, 1H); 7,99(d, 1H, J=8,5 Hz). (DMSO-d ₆)
2	(CH ₃) ₂ N-	H	H	H	H	H	H	2		156-158	3448, 2821, 1492, 1314, 1238, 1158, 1127, 1075, 1009, 752, 656, 645, 554, 543, 484.	2,08(s, 6H); 2,48(m, 2H); 4,10(t, 2H, J=6,6 Hz); 6,58(d, 1H, J=3,1 Hz); 6,85-6,96(m, 2H); 7,15(d, 1H, J=7,8 Hz); 7,19(d, 1H, J=3,1 Hz); 7,54-7,68(m, 2H); 7,83(dd, 1H, J=8,6 Hz, J'=1,8 Hz); 7,94(d, 1H, J=8,1 Hz). (DMSO-d ₆)




Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	A	m.p. °C	IR cm ⁻¹	¹ H-NMR (300 MHz), δ (solvent)
3	(CH ₃) ₂ N-	H	H	H	H	H	H		169-172	3279, 2943, 1403, 1318, 1162, 1132, 1003, 767, 745.	2,08(s, 6H); 2,46(m, 2H); 4,07(t, 2H, J=6,7 Hz); 6,45(d, 1H, J=3,2 Hz); 6,81(d, 1H, J=6,8 Hz); 6,88(t, 1H, J=7,7 Hz); 7,09(d, 1H, J=8,2 Hz); 7,12(d, 1H, J=3,2 Hz); 7,52(m, 1H); 7,62(m, 1H); 7,70(m, 1H); 8,01(d, 1H, J=8,2 Hz); 8,11(m, 2H); 8,87(d, 1H, J=8,4 Hz). (DMSO-d6)



Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	n	A	m.p. °C	IR cm ⁻¹	¹ H-NMR (300 MHz), δ (solvent)
4	(CH ₃) ₂ N-	H	H	H	H	H	H	2		137-140	3262, 2943, 1492, 1330, 1160, 1096, 750, 670, 590, 531.	2,10(s, 6H); 2,51(m, 2H); 4,14(t, 2H, J=6,6 Hz); 6,61(d, 1H, J=3,0 Hz); 6,90(d, 1H, J=7,0 Hz); 6,97(t, 1H, J=7,8 Hz); 7,19(d, 1H, J=7,8 Hz); 7,23(d, 1H, J=3,2 Hz); 7,36-7,69(m, 3H); 7,65(d, 2H, J=6,8 Hz); 7,76(AB sys, 2H, J=8,6 Hz); 7,82(AB sys, 2H, J=8,5 Hz,). (DMSO-d6)
5	(CH ₃) ₂ N-	H	H	H	H	H	H	2		47-54	3430, 3255, 2941, 2760, 1492, 1322, 1150, 748.	2,16(s, 6H); 2,59(m, 2H); 3,35(m, 4H); 4,24(t, 2H, J=6,3 Hz); 6,89(m, 1H, J=3,1 Hz); 7,05-7,11(m, 2H); 7,22(m, 1H); 7,28-7,38(m, 4H); 7,41(m, 2H); 7,74(d, 1H, J=7,18 Hz); 7,86(d, 1H, J=8,2 Hz). (DMSO-d6)



Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	n	A	m.p. °C	IR cm ⁻¹	¹ H-NMR (300 MHz), δ (solvent)
6	(CH ₃) ₂ N-	H	H	H	H	H	H	2		oil	2944, 2776, 1488, 1343, 1244, 1156, 1094, 751, 695	2,12(s, 6H); 2,52(m, 2H); 4,15(t, 2H, J=6,5 Hz); 6,51(d, 1H, J=3,0 Hz); 6,85(d, 1H, J=7,6 Hz); 6,97(m, 3H); 7,03(d, 2H, J=7,6 Hz); 7,20(d, 2H, J=8,1 Hz); 7,24(d, 1H, J=3,2 Hz); 7,42(t, 2H, J=7,9 Hz); 7,70(d, 2H, J=8,9 Hz). (DMSO-d6)
7	(CH ₃) ₂ N-	H	H	H	H	H	H	2		113-118	3255, 3072, 2935, 1570, 1492, 1340, 1169, 1138, 803, 747, 670, 594.	2,12(s, 6H); 2,54(t, 2H, J=6,6); 4,17(t, 2H, J=6,5 Hz); 6,42(d, 1H, J=3,1 Hz); 6,82(d, 1H, J=7,6 Hz); 7,02(t, 1H, J=8,0 Hz); 7,26-7,30(m, 2H); 7,63(d, 2H, J=1,9 Hz); 7,86(t, 1H, J=1,8 Hz). (DMSO-d6)



Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	A	m.p. °C	IR cm ⁻¹	¹ H-NMR (300 MHz), δ (solvent)
8	(CH ₃) ₂ N-	H	H	H	H	H	H		95-100		2,15(s, 6H); 2,56(t, 2H, J=6,2 Hz); 4,17(t, 2H, J=6,6 Hz); 6,31(d, 1H, J=2,8 Hz); 6,89(d, 1H, J=7,3 Hz); 7,01(m, 1H); 7,21(d, 1H, J=3,0 Hz); 7,27(d, 1H, 8,0 Hz); 7,49(d, 1H, J=4,4 Hz); 7,72(d, 1H, J=4,4 Hz). (DMSO-d6)

Pharmaceutical Data:

Binding of the new compounds of general formula (Ia and Ib and Ic) to
5 the 5-HT₆ receptor was determined as previously described.

The binding results for some of the compounds of the present invention
are indicated in the following table:

Example	Table
	% Inhibition 10 ⁻⁶ M
1	83.9
2	104.3
15 3	94.8
4	46.6
5	98.1
6	55.8
7	72.3

20

The daily posology in human medicine is comprised between 1 milligram
and 2 grams of medicinal product which may be administered in one or several
doses. The compositions are prepared under forms that are compatible with the
25 administration route used, preferably tablets, coated tablets, capsules,
suppositories, solutions or suspensions. These compositions are prepared via
known methods and comprise from 1 to 60% by weight of the drug substance
(compound of general formula I), and 40 to 99% by weight of the suitable
pharmaceutical vehicle compatible with the medicament substance and the
30 physical form of the composition used.

The formula of a tablet containing a product of the invention is provided by way of example:

Example of formula per tablet:

5

Example 1 5 mg

Lactose 60 mg

Crystalline cellulose 25 mg

Povidone K 90 5 mg

10 Pregelatinized starch 3 mg


Colloidal silicon dioxide 1 mg

Magnesium stearate 1 mg

Total weight per tablet 100 mg

CLAIMS

1. A sulfonamide compound of general formula (Ia),



(Ia),

wherein

R^1 represents a $-NR^8R^9$ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

R^4 is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^8 and R^9 , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

5 with the proviso that R^8 and R^9 are not hydrogen at the same time, and if one of them, R^8 or R^9 , is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_1 - C_4 aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms, or

10 R^8 and R^9 together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may
15 optionally contain at least one heteroatom as a ring member,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least
20 mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and


25 n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its
30 stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

2. A compound according to claim 1, characterized in that R^1 represents a - NR^8R^9 radical or a saturated or unsaturated optionally at least mono-substituted 5- or 6-membered cycloaliphatic radical, which may optionally
 5 contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- or 6-membered,

10

preferably R^1 represents a - NR^8R^9 radical or a radical chosen from the group consisting of



- wherein, if present, the dotted line represents an optional chemical bond,
 15 and R^{10} represents hydrogen, a linear or branched C_1-C_6 alkyl radical or a benzyl radical, preferably hydrogen or a C_1-C_2 alkyl radical.

3. A compound according to claim 1 or 2, characterized in that R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, a linear or
 20 branched, optionally at least mono-substituted C_1-C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2-C_6 alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2-C_6 alkynyl radical,

preferably R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

5

more preferably R^2 , R^3 , R^5 , R^6 and R^7 each represent hydrogen.

4. A compound according to one or more of claims 1 to 3, characterized in that R^4 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical

10

15

preferably R^4 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

more preferably R^4 represents hydrogen or a C_1 - C_2 alkyl radical.

5. A compound according to one or more of claims 1 to 4, characterized in that R^8 and R^9 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkynyl radical, or

20

25

R^8 and R^9 together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered heterocyclic ring which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- 6- or 7-


30

membered.

6. A compound according to claim 5, characterized in that R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched C_1 - C_{10} alkyl radical,

or

- R^8 and R^9 together with the bridging nitrogen atom form a radical chosen from the group consisting of



wherein R^{11} , if present, represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen, or a C_1 - C_2 alkyl radical.

15


7. A compound according to one or more of claims 1 to 6, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C_1 - C_6 alkylene group, an optionally at least mono-substituted C_2 - C_6 alkenylene group or an optionally at least mono-substituted C_2 - C_6 alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

25

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

5

or a radical chosen from the group consisting of



10 wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

15

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

20


wherein R^{14} is hydrogen or a linear or branched C_1 - C_6 alkyl,

m is 0, 1, 2, 3 or 4 and

5

m_1 is 1 or 2.

8. A sulfonamide compound of general formula (Ib),



10

wherein

R^1 represents a $-NR^8R^9$ radical,

15

R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

20

R^4 is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

25

R^8 and R^9 , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_{1-4} aliphatic radical,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and

n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

9. A compound according to claim 8, characterized in that R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical,

preferably R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

more preferably R^2 , R^3 , R^5 , R^6 and R^7 each represent hydrogen.

10. A compound according to claim 8 or 9, characterized in that R^4 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1-C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2-C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2-C_6 alkynyl radical,

preferably that R^4 represents hydrogen or a linear or branched, optionally at least substituted C_1-C_6 alkyl radical,

- more preferably R^4 represents hydrogen or a C_1-C_2 alkyl radical.


11. A compound according to one or more of claims 8 to 10, characterized in that R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1-C_4 alkyl radical,

preferably R^8 and R^9 represent hydrogen or a C_1-C_2 alkyl radical, with the proviso that R^8 and R^9 are not hydrogen at the same time.

12. A compound according to one or more of claims 8 to 11, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C_1-C_6 alkylene group, an optionally at least mono-substituted C_2-C_6 alkenylene group or an optionally at least mono-substituted C_2-C_6 alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

or a radical chosen from the group consisting of



5 wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

10

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

15

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

20

m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.

13. A compound according to one or more of claims 8 to 12 selected from
5 the group consisting of

[1] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,

10 [2] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphtalene-2-sulfonamide,

[3] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphtalene-1-sulfonamide,

15 [4] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenylbenzenesulfonamide,

[5] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-2-(naphtalene-1-yl)-ethanesulfonamide,
20

[6] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenoxybenzenesulfonamide,


25 [7] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-3,5-dichlorobenzenesulfonamide and

[8] 6-chloro-N-[1-(2-dimethylaminoethyl)-1H-indol-4-yl]-imidazo[2,1-b]thiazole-5-sulfonamide

30


and their corresponding salts and solvates.

14. A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, characterized in that a compound of general formula (II), or one of its suitably protected derivatives,



(II)

wherein A has the meaning according to one or more of claims 1 - 13, and X is an acceptable leaving group, preferably a halogen atom, more preferably chlorine is reacted with at least one 4-aminoindole of general formula (III), or one of its suitably protected derivatives;



(III)

wherein R¹-R⁷ and n have the meaning according to one or more of claims 1 - 13 to obtain the corresponding sulfonamide and optionally, from the latter, the protective groups may be removed if necessary.

15. A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, wherein R¹-R³, R⁵-R⁷, n and A have the meaning according to one or more of claims 1 - 13, and R⁴ represents C₁-C₆ alkyl, characterized by reacting at least one compound of general formula (Ia) and/or at least one compound of general formula (Ib), wherein R¹-R³, R⁵-R⁷, n and A have the meaning according to one or more of claims 1 - 13, and R⁴ represents an hydrogen atom, with an alkyl halogenide or dialkyl sulfate.

16. A process for preparing the salts, preferably the physiologically acceptable salts of the compounds of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, consisting of reacting at least one compound of the general formula (Ia) and/or at least one compound of the general formula (Ib) with a mineral acid or organic acid in a suitable solvent.
17. A medicament comprising least one compound according to one or more of claims 1 to 7 and optionally one or more pharmacologically acceptable excipients.
18. A medicament according to claim 17, for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),
- preferably for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia,

anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome.

5

19. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for 5-HT₆ receptor regulation.

10

20. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.

15

21. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the regulation of appetite.

22. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.

20

23. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

25

24. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.

30

25. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.

26. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 5 27. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 10 28. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 15 29. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
- 20 30. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 25 31. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.
32. The use of at least one compound according to one more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
- 30 33. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.

34. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 5
35. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 10
36. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 15
37. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 20
38. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.
- 25
39. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
- 30
40. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.

41. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 5
42. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 10
43. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
- 15
44. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for cognitive enhancement.
45. A medicament comprising at least one compound according to one or more of claims 8 to 13 and optionally one or more pharmacologically acceptable excipients.
- 20
46. A medicament according to claim 45 for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease,
- 25
- 30

Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),

5 preferably for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably
10 Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).

47. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for 5-HT₆ receptor regulation.
- 15 48. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.
- 20 49. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the regulation of appetite.
50. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the maintenance, increase
25 or reduction of body weight.
51. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

52. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.
- 5 53. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.
54. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 10
55. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 15
56. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 20
57. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
- 25
58. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 30 59. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.

- 5 60. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
61. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.
- 10 62. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 15 63. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 20 64. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 25 65. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
66. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
- 30 67. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.

- 5
68. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.
69. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 10
70. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 15
71. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
- 20
72. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for cognitive enhancement.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/008512

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/4045 C07D209/08 C07D409/12 C07D513/04 A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 03/042175 A (ESTEVE LABOR DR) 22 May 2003 (2003-05-22) page 33, line 1 - page 35, line 3; claims; examples -----	1-72
Y	EP 0 815 861 A (HOFFMANN LA ROCHE) 7 January 1998 (1998-01-07) compounds of formula (ie) page 14, line 3 - page 15, line 10; claims -----	1-72
Y	WO 02/060871 A (FLAUGH MICHAEL EDWARD ; GILLIG JAMES RONALD (US); HEINZ LAWRENCE JOSEP) 8 August 2002 (2002-08-08) page 102, line 30 - page 116, line 17; claims; examples 2,8-10,18,-21,23-,25,28,30,48-50,59,60,67 ----- -/--	1-72



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 November 2004

Date of mailing of the international search report

22/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gavriliu, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/008512

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3 472 870 A (GOULD BARBARA E ET AL) 14 October 1969 (1969-10-14) the whole document	1-72
A	WO 00/46915 A (ERICSSON INC) 10 August 2000 (2000-08-10) page 29, line 30 - page 36, line 15; claims; examples 1,4,5,7,9; table 1	1-72

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/008512

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03042175	A	22-05-2003	ES 2187300 A1 CA 2466965 A1 EP 1445252 A1 WO 03042175 A1 US 2003191124 A1	16-05-2003 22-05-2003 11-08-2004 22-05-2003 09-10-2003
EP 0815861	A	07-01-1998	EP 0815861 A1 AT 205714 T AU 694696 B2 AU 2841697 A BR 9703788 A CA 2209018 A1 CN 1170574 A ,B CZ 9702002 A3 DE 59704640 D1 DK 815861 T3 ES 2163071 T3 HK 1007865 A3 HK 1007865 A1 HR 970349 A1 HU 9701096 A2 IL 121141 A JP 3032176 B2 JP 10067734 A KR 260480 B1 MA 24237 A1 NO 972983 A NZ 328146 A PL 320822 A1 PT 815861 T RU 2192257 C2 SG 77139 A1 TR 9700550 A2 TW 502013 B US 6030976 A US 5932599 A US 5939451 A ZA 9705561 A	07-01-1998 15-10-2001 23-07-1998 22-01-1998 17-11-1998 28-12-1997 21-01-1998 14-01-1998 25-10-2001 21-01-2002 16-01-2002 30-04-1999 03-05-2002 30-04-1998 01-02-1999 23-12-2001 10-04-2000 10-03-1998 01-07-2000 31-12-1997 29-12-1997 28-10-1999 05-01-1998 28-02-2002 10-11-2002 19-12-2000 21-01-1998 11-09-2002 29-02-2000 03-08-1999 17-08-1999 29-12-1997
WO 02060871	A	08-08-2002	BR 0206595 A CA 2433351 A1 CN 1489591 T EP 1377580 A2 JP 2004526699 T WO 02060871 A2 US 2004102481 A1	13-07-2004 08-08-2002 14-04-2004 07-01-2004 02-09-2004 08-08-2002 27-05-2004
US 3472870	A	14-10-1969	DE 1695478 A1 FR 6605 M FR 1601070 A GB 1198128 A	20-01-1972 06-01-1969 10-08-1970 08-07-1970
WO 0046915	A	10-08-2000	US 6043706 A AU 2634700 A WO 0046915 A1	28-03-2000 25-08-2000 10-08-2000